Russell Investments Group, Ltd. Atara Biotherapeutics, Inc. Transaction History

Russell Investments Group, Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.41 - $2.31 $7,836 - $12,838	-5,558 Reduced 97.32%	153 $0
Q1 2023 May 09, 2023	BUY	$2.8 - $5.46 $15,990 - $31,182	5,711 New	5,711 $16,000
Q3 2021 Nov 08, 2021	SELL	$11.99 - $17.9 $250,567 - $374,074	-20,898 Closed	0 $0
Q2 2021 Aug 04, 2021	SELL	$12.89 - $16.58 $25,315 - $32,563	-1,964 Reduced 8.59%	20,898 $324,000
Q1 2021 May 10, 2021	BUY	$14.0 - $20.72 $320,068 - $473,700	22,862 New	22,862 $327,000
Q4 2020 Feb 08, 2021	SELL	$12.67 - $26.23 $321,982 - $666,582	-25,413 Closed	0 $0
Q3 2020 Nov 09, 2020	SELL	$11.92 - $15.87 $16,986 - $22,614	-1,425 Reduced 5.31%	25,413 $328,000
Q2 2020 Aug 05, 2020	SELL	$7.53 - $14.93 $178,272 - $353,467	-23,675 Reduced 46.87%	26,838 $390,000
Q3 2019 Nov 01, 2019	BUY	$12.03 - $19.94 $607,671 - $1.01 Million	50,513 New	50,513 $712,000
Q4 2017 Feb 06, 2018	SELL	$13.2 - $18.1 $135,418 - $185,687	-10,259 Closed	0 $0
Q3 2017 Nov 07, 2017	BUY	$13.25 - $17.05 $135,931 - $174,915	10,259	10,259 $170,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $949M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.